Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Bullboard Posts
Comment by JayjayUSA12007on Jun 02, 2018 8:33pm
135 Views
Post# 28116306

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Why paying off EMD Sorono ?

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Why paying off EMD Sorono ?
palinc2000 wrote: I think it is fair to assume that the prepayment was done with an ulterior motive in mind.
Maybe Jay Jay has a point ....... Maybe its a valuation tool !
For what purpose? Buyout or merger not necessarily.
Maybe the goal is a Nasdaq Listing and a US Offering  in a not too distant future.I predict that Th  will  publish  financial statements in US dollars rather than in Canadian $ starting Dec 2018.


Exactly! Thera management seems to beef up Thera balance sheet in preparation for something related to the valuation of the company..
I dont think  Nasdaq listing requirements would have anything to do with EBITDA. Without this move, Thera is already qualified for Nasdaq listing (see below):
Link: https://venturelawcorp.com/listing-requirements-nasdaq/

A US secondary offering doesn't seems to be realistic without a Nasdaq listing. So, it is even less likely than Nasdaq listing.
We are left with the possibility of a buyout or merger. I 've seen this scenario before and last time I have been through was an all-cash buyout at $31/share from current SP of $13.
I think it would be a fair offer. Opinion ?

Bullboard Posts